Zai Lab is a holding company. Through its subsidiaries, Co. is a commercial-stage biopharmaceutical company focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of unmet medical need in the China and global markets, including in the fields of oncology, infectious and autoimmune diseases. Co.'s products are: Niraparib, a selective oral, small molecule PARP 1/2 inhibitor with the potential to be a drug for treatment across multiple solid tumor types in China; and Optune, a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die. The ZLAB stock yearly return is shown above.
The yearly return on the ZLAB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ZLAB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|